Gemtero Indications/Uses

Non-small cell lung cancer: Gemcitabine in combination with Cisplatin is indicated as first line treatment of patients with locally advanced (inoperable stage IIIA and IIIB) or metastatic (stage IV) non-small cell lung cancer. Gemcitabine is indicated for the palliative treatment of adult patients with locally advanced or metastatic non-small cell lung cancer.
Pancreatic cancer: Gemcitabine is indicated as first-line treatment of patients with locally advanced (non-resectable Stage II or Stage III) or metastatic (Stage IV) adenocarcinoma of the pancreas. Gemcitabine is also indicated for patients previously treated with 5-FU.
Bladder cancer: Gemcitabine is indicated for treatment of advanced bladder cancer (muscle invasive Stage IV tumours with or without metastases) in combination with Cisplatin therapy.
Breast cancer: Gemcitabine in combination with Paclitaxel is indicated for the treatment of patients with unresectable, locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. Prior chemotherapy should have included as Anthracycline unless clinically contraindicated.
Ovarian cancer: Gemcitabine, alone or in combination, is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma who have relapsed following platinum-based therapy.
Other therapeutic activity: Gemcitabine alone or in combination has shown activity in advanced breast and ovarian cancer.